Liver Foundation Appoints NASH Advocate as Board Chair
Event summary
- David Frank, Senior Product Manager at Wells Fargo Securities, was elected Chair of the American Liver Foundation (ALF) board, succeeding Emmanuel Thomas, MD, PhD.
- Outgoing Chair Thomas highlights ALF’s recent achievements, including $1.1 million in research funding, a partnership with the VA/VHA, and the creation of a Living Donor Network.
- Frank’s involvement with ALF began in 2014 following his mother’s death from MASH (formerly NASH), and he founded the NASH AWARE blog to raise awareness.
- Frank succeeds Thomas, who served as chair for three years and was on the board for ten, including leadership roles on the Nominating and Investment Committees.
The big picture
The appointment of a finance professional and NASH advocate to lead a major liver disease foundation signals a potential shift towards more data-driven and targeted fundraising and awareness campaigns. With over 100 million Americans affected by liver disease, the pressure to accelerate research and patient outreach is significant, and the new chair’s emphasis on speed and scale indicates a desire for more aggressive action. The Living Donor Network initiative, coupled with the VA partnership, suggests a growing focus on innovative solutions to address the organ shortage crisis.
What we're watching
- Strategic Focus
- Frank's personal connection to MASH and his advocacy work suggest a sharpened focus on this specific disease area, potentially shifting resource allocation within ALF.
- Fundraising
- The new chair's background in finance may influence fundraising strategies, potentially leading to a greater emphasis on corporate partnerships and data-driven philanthropy.
- Public Profile
- Frank’s existing public profile and blog, NASH AWARE, could amplify ALF’s message and expand its reach, but also introduces potential reputational risks if messaging diverges.
Related topics